Spironolactone as an Adjunctive Treatment in Neovascular Age-Related Macular Degeneration

Abstract

Neovascular age-related macular degeneration (AMD) is a potentially sight-threatening condition. The current standard-of-care treatment regimen is serial intravitreal antivascular endothelial growth factor injections. While these typically have great success, they do carry exceptional treatment burden on the patient, cost burden due to their required frequency of use, and the risk of endophthalmitis, which can be devastating. This case report explores an alternative potential option as a treatment adjunct for neovascular AMD (nAMD), and identifies some of the overlap between nAMD and central serous chorioretionpathy. Future research is needed to better understand the role of mineralocorticoid receptor antagonist treatment in this disease spectrum.

Keywords

• Neovascular age-related macular degeneration
• Central serous chorioretinopathy
• Mineralocorticoid receptor antagonists
• Eplerenone
• Spironolactone